Heartvue.ai and Innolitics Gain FDA Clearance for Cardiac MRI AI
Brentwood, Tennessee & Austin, Texas, USA, September 3, 2026 Heartvue.ai and Innolitics have announced that the U.S. Food and...
Akeso
Advertisement
Akeso Reports Ivonescimab OS Benefit in HARMONi-2
Hong Kong, September 3, 2026 Akeso, Inc. has announced that a prespecified interim analysis of overall survival (OS) in...
HUTCHMED and GSK Partner on KRAS-EGFR Cancer Therapy
Hong Kong, Shanghai & Florham Park, New Jersey, USA, September 3, 2026 HUTCHMED (China) Limited and GSK have entered...
Akeso Reports 2026 Growth, Advances Global Drug Pipeline
HONG KONG, Aug 27, 2026 Akeso, Inc. announced its 2026 interim results, reporting record commercial drug sales while advancing...
Akeso Advances AK157D1 B7-H3 ADC Into Phase I
Hong Kong, August 21, 2026 Akeso, Inc. has announced that its investigational B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received...
Advertisements
Akeso Doses First Patient in HER3 ADC Lung Cancer Trial
Hong Kong, July 27, 2026 Akeso, Inc. has announced that the first patient has been dosed in the Phase...
Akeso Starts Phase II Trial of AK146D1 for Advanced NSCLC
HONG KONG, July 20, 2026 Akeso, Inc. has announced a significant milestone in its oncology pipeline with the first...
Akeso Wins NMPA Approval for Gumokimab in Plaque Psoriasis
HONG KONG, June 11, 2026 Akeso, Inc. announced that China’s National Medical Products Administration (NMPA) has approved gumokimab (AK111,...
Akeso Reports Positive Phase II Ligufalimab AML Data at EHA 2026
HONG KONG, May 15, 2026 Akeso, Inc. announced positive Phase II clinical trial results for ligufalimab (AK117) in frontline...
Akeso Cadonilimab Combo Shows Strong Survival in Pancreatic Cancer
Hong Kong, April 20, 2026 In a significant breakthrough in oncology immunotherapy, Akeso, Inc. has announced promising Phase II...
Advertisement
